{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:30:03Z","timestamp":1790271003950,"version":"4.1.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s10787-025-01758-2","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T10:09:15Z","timestamp":1748513355000},"page":"2377-2407","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Systematic review of comparative studies on emerging psoriasis treatments: comparing biologics with biologics, small molecule inhibitors with small molecule inhibitors, and biologics with small molecule inhibitors"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-7047-8834","authenticated-orcid":false,"given":"Seyed Iraj","family":"Azimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5878-9778","authenticated-orcid":false,"given":"Alireza","family":"Jafarzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1249-4429","authenticated-orcid":false,"given":"Azadeh","family":"Goodarzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,29]]},"reference":[{"issue":"1","key":"1758_CR1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","volume":"88","author":"AW Armstrong","year":"2023","unstructured":"Armstrong AW, Gooderham M, Warren RB, Papp KA, Strober B, Tha\u00e7i D, Morita A, Szepietowski JC, Imafuku S, Colston E, Throup J, Kundu S, Schoenfeld S, Linaberry M, Banerjee S, Blauvelt A (2023a) Deucravacitinib versus placebo and Apremilast in moderate to severe plaque Psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol 88(1):29\u201339. https:\/\/doi.org\/10.1016\/j.jaad.2022.07.002","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"1758_CR2","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1007\/s13555-023-00977-1","volume":"13","author":"AW Armstrong","year":"2023","unstructured":"Armstrong AW, Park SH, Patel V, Hogan M, Wang WJ, Davidson D, Chirikov V (2023b) Matching-adjusted indirect comparison of the long-term efficacy of deucravacitinib versus adalimumab for moderate to severe plaque psoriasis. Dermatol Ther (Heidelb) 13(11):2589\u20132603. https:\/\/doi.org\/10.1007\/s13555-023-00977-1","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"11","key":"1758_CR3","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1007\/s13555-023-01034-7","volume":"13","author":"AW Armstrong","year":"2023","unstructured":"Armstrong AW, Warren RB, Zhong Y, Zhuo J, Cichewicz A, Kadambi A, Junqueira D, Westley T, Kisa R, Daamen C, Augustin M (2023c) Short-, mid-, and long-term efficacy of deucravacitinib versus biologics and nonbiologics for plaque psoriasis: a network meta-analysis. Dermatol Ther (Heidelb) 13(11):2839\u20132857. https:\/\/doi.org\/10.1007\/s13555-023-01034-7","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"9993","key":"1758_CR4","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/s0140-6736(14)62113-9","volume":"386","author":"H Bachelez","year":"2015","unstructured":"Bachelez H, van de Kerkhof PC, Strohal R, Kubanov A, Valenzuela F, Lee JH, Yakusevich V, Chimenti S, Papacharalambous J, Proulx J, Gupta P, Tan H, Tawadrous M, Valdez H, Wolk R (2015) Tofacitinib versus Etanercept or placebo in moderate-to-severe chronic plaque Psoriasis: a phase 3 randomised non-inferiority trial. Lancet 386(9993):552\u2013561. https:\/\/doi.org\/10.1016\/s0140-6736(14)62113-9","journal-title":"Lancet"},{"issue":"4","key":"1758_CR5","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s13555-018-0265-y","volume":"8","author":"J Bagel","year":"2018","unstructured":"Bagel J, Nia J, Hashim PW, Patekar M, de Vera A, Hugot S, Sheng K, Xia S, Gilloteau I, Muscianisi E, Blauvelt A, Lebwohl M (2018) Secukinumab is superior to ustekinumab in clearing skin in patients with moderate to severe plaque psoriasis (16-week CLARITY results). Dermatol Ther (Heidelb) 8(4):571\u2013579. https:\/\/doi.org\/10.1007\/s13555-018-0265-y","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"1758_CR6","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/jdv.16558","volume":"35","author":"J Bagel","year":"2021","unstructured":"Bagel J, Blauvelt A, Nia J, Hashim P, Patekar M, de Vera A, Ahmad K, Paguet B, Xia S, Muscianisi E, Lebwohl M (2021) Secukinumab maintains superiority over Ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque Psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY). J Eur Acad Dermatol Venereol 35(1):135\u2013142. https:\/\/doi.org\/10.1111\/jdv.16558","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"1758_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.8066","volume":"11","author":"AS Bazargan","year":"2023","unstructured":"Bazargan AS, Jafarzadeh A, Nobari NN (2023) Successful treatment of resistant plantar ulcerative lichen planus with Tofacitinib: a case report and comprehensive review of the literature. Clin Case Rep 11(10):e8066. https:\/\/doi.org\/10.1002\/ccr3.8066","journal-title":"Clin Case Rep"},{"issue":"5","key":"1758_CR8","doi-asserted-by":"publisher","DOI":"10.1111\/srt.13718","volume":"30","author":"E Behrangi","year":"2024","unstructured":"Behrangi E, Moodi F, Jafarzadeh A, Goodarzi A (2024) Paradoxical and bimodal immune-mediated dermatological side effects of TNF-\u03b1 inhibitors: a comprehensive review. Skin Res Technol 30(5):e13718. https:\/\/doi.org\/10.1111\/srt.13718","journal-title":"Skin Res Technol"},{"issue":"3","key":"1758_CR9","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, Papp KA, Griffiths CEM, Randazzo B, Wasfi Y, Shen Y-K, Li S, Kimball AB (2017a) Efficacy and safety of Guselkumab, an anti-interleukin-23 monoclonal antibody, compared with Adalimumab for the continuous treatment of patients with moderate to severe Psoriasis: results from the phase III, double-blinded, placebo- and active comparator\u2013controlled VOYAGE 1 trial. J Am Acad Dermatol 76(3):405\u2013417. https:\/\/doi.org\/10.1016\/j.jaad.2016.11.041","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1758_CR10","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaad.2016.08.008","volume":"76","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, Reich K, Tsai TF, Tyring S, Vanaclocha F, Kingo K, Ziv M, Pinter A, Vender R, Hugot S, You R, Milutinovic M, Tha\u00e7i D (2017b) Secukinumab is superior to Ustekinumab in clearing skin of subjects with moderate-to-severe plaque Psoriasis up to 1 year: results from the CLEAR study. J Am Acad Dermatol 76(1):60-69.e69. https:\/\/doi.org\/10.1016\/j.jaad.2016.08.008","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1758_CR11","doi-asserted-by":"publisher","first-page":"AB173","DOI":"10.1016\/j.jaad.2018.05.707","volume":"79","author":"A Blauvelt","year":"2018","unstructured":"Blauvelt A, Lomaga M, Burge R, Zhu B, Henneges C, Shen W, Shrom D, Dossnbach M, Pinter A, Blauvelt A, Lomaga M, Burge R, Zhu B, Henneges C, Shen W, Shrom D, Dossnbach M, Pinter A (2018) Ixekizumab provides greater cumulative benefits versus Ustekinumab over 24 weeks for patients with moderate-to-severe Psoriasis in a randomized double-blind phase 3b clinical trial. J Am Acad Dermatol 79(3):AB173\u2013AB173","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1758_CR12","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1001\/jamadermatol.2020.0723","volume":"156","author":"A Blauvelt","year":"2020","unstructured":"Blauvelt A, Leonardi CL, Gooderham M, Papp KA, Philipp S, Wu JJ, Igarashi A, Flack M, Geng Z, Wu T, Camez A, Williams D, Langley RG (2020a) Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial. JAMA Dermatol 156(6):649\u2013658. https:\/\/doi.org\/10.1001\/jamadermatol.2020.0723","journal-title":"JAMA Dermatol"},{"issue":"2","key":"1758_CR13","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1080\/09546634.2019.1587146","volume":"31","author":"A Blauvelt","year":"2020","unstructured":"Blauvelt A, Lomaga M, Burge R, Zhu B, Shen W, Shrom D, Dossenbach M, Pinter A (2020b) Greater cumulative benefits from Ixekizumab versus Ustekinumab treatment over 52 weeks for patients with moderate-to-severe Psoriasis in a randomized, double-blinded phase 3b clinical trial. J Dermatol Treat 31(2):141\u2013146. https:\/\/doi.org\/10.1080\/09546634.2019.1587146","journal-title":"J Dermatol Treat"},{"issue":"6","key":"1758_CR14","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1111\/bjd.18851","volume":"182","author":"A Blauvelt","year":"2020","unstructured":"Blauvelt A, Papp K, Gottlieb A, Jarell A, Reich K, Maari C, Gordon KB, Ferris LK, Langley RG, Tada Y, Lima RG, Elmaraghy H, Gallo G, Renda L, Park SY, Burge R, Bagel J (2020c) A head-to-head comparison of Ixekizumab vs. Guselkumab in patients with moderate-to-severe plaque Psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. Br J Dermatol 182(6):1348\u20131358. https:\/\/doi.org\/10.1111\/bjd.18851","journal-title":"Br J Dermatol"},{"issue":"6","key":"1758_CR15","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1111\/bjd.19509","volume":"184","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Leonardi C, Elewski B, Crowley JJ, Guenther LC, Gooderham M, Langley RG, Vender R, Pinter A, Griffiths CEM, Tada Y, Elmaraghy H, Lima RG, Gallo G, Renda L, Burge R, Park SY, Zhu B, Papp K (2021) A head-to-head comparison of Ixekizumab vs Guselkumab in patients with moderate-to-severe plaque Psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial. Br J Dermatol 184(6):1047\u20131058. https:\/\/doi.org\/10.1111\/bjd.19509","journal-title":"Br J Dermatol"},{"issue":"4","key":"1758_CR16","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1080\/09546634.2021.1959504","volume":"33","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Armstrong AW, Langley RG, Gebauer K, Tha\u00e7i D, Bagel J, Guenther LC, Paul C, Randazzo B, Flavin S, Hsu MC, You Y, Reich K (2022) Efficacy of Guselkumab versus Secukinumab in subpopulations of patients with moderate-to-severe plaque Psoriasis: results from the ECLIPSE study. J Dermatol Treat 33(4):2317\u20132324. https:\/\/doi.org\/10.1080\/09546634.2021.1959504","journal-title":"J Dermatol Treat"},{"key":"1758_CR17","first-page":"10S","volume":"147","author":"C Conrad","year":"2017","unstructured":"Conrad C, Gottlieb A, Tha\u00e7i D, Blauvelt A, Bhosekar V, Milutinovic M, Karyekar C, Conrad C, Gottlieb AB, Thaci D, Blauvelt A, Bhosekar V, Milutinovic M, Karyekar C (2017) Sustained improvements in skin symptoms, physical functioning, and quality of life with Secukinumab versus Ustekinumab in patients with moderate-to-severe Psoriasis and concomitant psoriatic arthritis: 52 week results from the clear study. Swiss Med Wkly 147:10S-11S","journal-title":"Swiss Med Wkly"},{"issue":"2","key":"1758_CR18","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s13555-021-00679-6","volume":"12","author":"JJ Crowley","year":"2022","unstructured":"Crowley JJ, Langley RG, Gordon KB, Pinter A, Ferris LK, Rubant S, Photowala H, Xue Z, Wu T, Zhan T, Beeck S, Shah M, Warren RB (2022) Efficacy of risankizumab versus secukinumab in patients with moderate-to-severe psoriasis: subgroup analysis from the IMMerge Study. Dermatol Ther (Heidelb) 12(2):561\u2013575. https:\/\/doi.org\/10.1007\/s13555-021-00679-6","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1758_CR19","doi-asserted-by":"publisher","first-page":"adv41053","DOI":"10.2340\/actadv.v104.41053","volume":"104","author":"E Errichetti","year":"2024","unstructured":"Errichetti E, Wolf P, Khattri S, Gorecki P, Miller M, Jiang J, Han C, Kirby B (2024) Patients with persistent mild psoriasis after treatment with ustekinumab achieved greater improvements in skin clearance and patient-reported outcomes after switching to guselkumab in the phase 3 NAVIGATE trial. Acta Derm Venereol 104:adv41053. https:\/\/doi.org\/10.2340\/actadv.v104.41053","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"1758_CR20","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1001\/jamadermatol.2018.0793","volume":"154","author":"P Foley","year":"2018","unstructured":"Foley P, Gordon K, Griffiths CEM, Wasfi Y, Randazzo B, Song M, Li S, Shen YK, Blauvelt A (2018) Efficacy of guselkumab compared with adalimumab and placebo for psoriasis in specific body regions: a secondary analysis of 2 randomized clinical trials. JAMA Dermatol 154(6):676\u2013683. https:\/\/doi.org\/10.1001\/jamadermatol.2018.0793","journal-title":"JAMA Dermatol"},{"issue":"2","key":"1758_CR21","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1056\/NEJMoa1501646","volume":"373","author":"KB Gordon","year":"2015","unstructured":"Gordon KB, Duffin KC, Bissonnette R, Prinz JC, Wasfi Y, Li S, Shen YK, Szapary P, Randazzo B, Reich K (2015) A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis. N Engl J Med 373(2):136\u2013144. https:\/\/doi.org\/10.1056\/NEJMoa1501646","journal-title":"N Engl J Med"},{"issue":"11","key":"1758_CR22","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1111\/jdv.15012","volume":"32","author":"KB Gordon","year":"2018","unstructured":"Gordon KB, Armstrong AW, Han C, Foley P, Song M, Wasfi Y, You Y, Shen YK, Reich K (2018a) Anxiety and depression in patients with moderate-to-severe Psoriasis and comparison of change from baseline after treatment with Guselkumab vs. Adalimumab: results from the Phase 3 VOYAGE 2 study. J Eur Acad Dermatol Venereol 32(11):1940\u20131949. https:\/\/doi.org\/10.1111\/jdv.15012","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10148","key":"1758_CR23","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/s0140-6736(18)31713-6","volume":"392","author":"KB Gordon","year":"2018","unstructured":"Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, Papp KA, Sofen H, Puig L, Foley P, Ohtsuki M, Flack M, Geng Z, Gu Y, Valdes JM, Thompson EHZ, Bachelez H (2018b) Efficacy and safety of Risankizumab in moderate-to-severe plaque Psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and Ustekinumab-controlled phase 3 trials. Lancet 392(10148):650\u2013661. https:\/\/doi.org\/10.1016\/s0140-6736(18)31713-6","journal-title":"Lancet"},{"issue":"3","key":"1758_CR24","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1111\/j.1365-2133.2011.10418.x","volume":"165","author":"AB Gottlieb","year":"2011","unstructured":"Gottlieb AB, Leonardi C, Kerdel F, Mehlis S, Olds M, Williams DA (2011) Efficacy and safety of Briakinumab vs. Etanercept and placebo in patients with moderate to severe chronic plaque Psoriasis. Br J Dermatol 165(3):652\u2013660. https:\/\/doi.org\/10.1111\/j.1365-2133.2011.10418.x","journal-title":"Br J Dermatol"},{"issue":"2","key":"1758_CR25","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1056\/NEJMoa0810652","volume":"362","author":"CE Griffiths","year":"2010","unstructured":"Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, Guzzo C, Xia Y, Zhou B, Li S, Dooley LT, Goldstein NH, Menter A (2010) Comparison of Ustekinumab and Etanercept for moderate-to-severe Psoriasis. N Engl J Med 362(2):118\u2013128. https:\/\/doi.org\/10.1056\/NEJMoa0810652","journal-title":"N Engl J Med"},{"issue":"9993","key":"1758_CR26","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/s0140-6736(15)60125-8","volume":"386","author":"CE Griffiths","year":"2015","unstructured":"Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K (2015) Comparison of Ixekizumab with Etanercept or placebo in moderate-to-severe Psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet 386(9993):541\u2013551. https:\/\/doi.org\/10.1016\/s0140-6736(15)60125-8","journal-title":"Lancet"},{"issue":"3","key":"1758_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/srt.13642","volume":"30","author":"A Jafarzadeh","year":"2024","unstructured":"Jafarzadeh A, Pour Mohammad A, Khosravi M, Amiri S, Rasouli A, Keramati H, Goodarzi A (2024) A systematic review of case series and clinical trials investigating systemic oral or injectable therapies for the treatment of vitiligo. Skin Res Technol 30(3):e13642. https:\/\/doi.org\/10.1111\/srt.13642","journal-title":"Skin Res Technol"},{"key":"1758_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-025-01675-4","author":"A Jafarzadeh","year":"2025","unstructured":"Jafarzadeh A, Behrangi E, Khosravi M, Falakeh S, Amiri JK, Goodarzi A (2025) Emerging treatments for dermatologic diseases in infants, children, and adolescents: a systematic review of clinical trials on biologics and small molecule inhibitors. Inflammopharmacology. https:\/\/doi.org\/10.1007\/s10787-025-01675-4","journal-title":"Inflammopharmacology"},{"issue":"6","key":"1758_CR29","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1007\/s13555-021-00618-5","volume":"11","author":"G Kokolakis","year":"2021","unstructured":"Kokolakis G, Vadstrup K, Hansen JB, Carrascosa JM (2021) Increased skin clearance and quality of life improvement with brodalumab compared with ustekinumab in psoriasis patients with aggravating lifestyle factors. Dermatol Ther (Heidelb) 11(6):2027\u20132042. https:\/\/doi.org\/10.1007\/s13555-021-00618-5","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"10","key":"1758_CR30","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1111\/exd.14828","volume":"32","author":"J Krueger","year":"2023","unstructured":"Krueger J, Langley RG, Nigen S, Kasparek T, Di Comite G, Ortmann CE, Garcet S, Kolbinger F, Reich K (2023) Secukinumab versus Guselkumab in the complete resolution of Ustekinumab-resistant psoriatic plaques: The ARROW study. Exp Dermatol 32(10):1834\u20131847. https:\/\/doi.org\/10.1111\/exd.14828","journal-title":"Exp Dermatol"},{"issue":"4","key":"1758_CR31","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s13555-021-00545-5","volume":"11","author":"J Lambert","year":"2021","unstructured":"Lambert J, Hansen JB, Sohrt A, Puig L (2021) Dermatology life quality index in patients with moderate-to-severe plaque psoriasis treated with brodalumab or ustekinumab. Dermatol Ther (Heidelb) 11(4):1265\u20131275. https:\/\/doi.org\/10.1007\/s13555-021-00545-5","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1758_CR32","first-page":"14","volume":"12","author":"R Langley","year":"2014","unstructured":"Langley R, Reich K, Griffiths C, Puig L, Spelman L, Zaldivar E, Wasel N, Salko T, Notter M, Helou S, Papavassilis C, Langley R, Reich K, Griffiths C, Puig L, Spelman L, Zaldivar ER, Wasel N, Salko T, Papavassilis C (2014a) Secukinumab compared with placebo and Etanercept: The first 52-week head-to-head comparison of two biologics in a randomized, double-blind phase 3 study in subjects with moderate-to-severe plaque Psoriasis (FIXTURE). J Deutsch Dermatol Gesellsch 12:14\u201314","journal-title":"J Deutsch Dermatol Gesellsch"},{"issue":"4","key":"1758_CR33","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa1314258","volume":"371","author":"RG Langley","year":"2014","unstructured":"Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai TF, Wasel N, Tyring S, Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C (2014b) Secukinumab in plaque Psoriasis\u2013results of two phase 3 trials. N Engl J Med 371(4):326\u2013338. https:\/\/doi.org\/10.1056\/NEJMoa1314258","journal-title":"N Engl J Med"},{"issue":"14","key":"1758_CR34","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","volume":"373","author":"M Lebwohl","year":"2015","unstructured":"Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, Papp K, Spelman L, Toth D, Kerdel F, Armstrong AW, Stingl G, Kimball AB, Bachelez H, Wu JJ, Crowley J, Langley RG, Blicharski T, Paul C et al (2015) Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med 373(14):1318\u20131328. https:\/\/doi.org\/10.1056\/NEJMoa1503824","journal-title":"N Engl J Med"},{"issue":"9","key":"1758_CR35","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1111\/1346-8138.15004","volume":"46","author":"MG Lee","year":"2019","unstructured":"Lee MG, Huang YH, Lee JH, Lee SC, Kim TG, Aw DC, Bao W, Dee CMA, Guana A, Tsai TF (2019) Secukinumab demonstrates superior efficacy and a faster response in clearing skin in Asian subjects with moderate to severe plaque Psoriasis compared with Ustekinumab: subgroup analysis from the CLEAR study. J Dermatol 46(9):752\u2013758. https:\/\/doi.org\/10.1111\/1346-8138.15004","journal-title":"J Dermatol"},{"key":"1758_CR36","first-page":"38","volume":"165","author":"A Menter","year":"2011","unstructured":"Menter A, Gottlieb A, Leonardi C, Kerdel F, Gu Y, Valdes J, Menter A, Gottlieb A, Leonardi C, Kerdel F, Gu Y, Valdes J (2011) Efficacy and safety results of Briakinumab vs. Etanercept and placebo in patients with moderate to severe chronic plaque Psoriasis. Br J Dermatol 165:38\u201339","journal-title":"Br J Dermatol"},{"issue":"10","key":"1758_CR37","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1111\/jdv.14237","volume":"31","author":"A Menter","year":"2017","unstructured":"Menter A, Warren RB, Langley RG, Merola JF, Kerr LN, Dennehy EB, Shrom D, Amato D, Okubo Y, Reich K (2017) Efficacy of Ixekizumab compared to Etanercept and placebo in patients with moderate-to-severe plaque Psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3). J Eur Acad Dermatol Venereol 31(10):1686\u20131692. https:\/\/doi.org\/10.1111\/jdv.14237","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1758_CR38","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-eular.1980","author":"J Merola","year":"2019","unstructured":"Merola J, Shu LI, Hsu M-C, Karyekar C, Flavin S, Randazzo B, Coates L (2019) SAT0390 guselkumab was more effective than secukinumab in patients with plaque psoriasis and the subset of patients with self-reported psoriatic arthritis in the randomized, double-blind, head-to-head comparison study eclipse over 1 year. Ann Rheumat Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2019-eular.1980","journal-title":"Ann Rheumat Dis"},{"issue":"9","key":"1758_CR39","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1111\/jdv.14910","volume":"32","author":"KA Papp","year":"2018","unstructured":"Papp KA, Blauvelt A, Kimball AB, Han C, Randazzo B, Wasfi Y, Shen YK, Li S, Griffiths CEM (2018) Patient-reported symptoms and signs of moderate-to-severe Psoriasis treated with Guselkumab or Adalimumab: results from the randomized VOYAGE 1 trial. J Eur Acad Dermatol Venereol 32(9):1515\u20131522. https:\/\/doi.org\/10.1111\/jdv.14910","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"1758_CR40","doi-asserted-by":"publisher","first-page":"e542","DOI":"10.1016\/S2665-9913(23)00120-0","volume":"5","author":"K Papp","year":"2023","unstructured":"Papp K, Warren RB, Green L, Reich K, Langley RG, Paul C, Asahina A, Johnson L, Arora V, Osuntokun O, Lebwohl M (2023) Safety and efficacy of Mirikizumab versus Secukinumab and placebo in the treatment of moderate-to-severe plaque Psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study. Lancet Rheumatol 5(9):e542\u2013e552. https:\/\/doi.org\/10.1016\/S2665-9913(23)00120-0","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"1758_CR41","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jaad.2018.06.039","volume":"80","author":"C Paul","year":"2019","unstructured":"Paul C, Griffiths CEM, van de Kerkhof PCM, Puig L, Dutronc Y, Henneges C, Dossenbach M, Hollister K, Reich K (2019) Ixekizumab provides superior efficacy compared with Ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study. J Am Acad Dermatol 80(1):70-79.e73. https:\/\/doi.org\/10.1016\/j.jaad.2018.06.039","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1758_CR42","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.jaad.2017.10.025","volume":"78","author":"L Puig","year":"2018","unstructured":"Puig L, Augustin M, Blauvelt A, Gottlieb AB, Vender R, Korman NJ, Tha\u00e7i D, Zhao Y, Gilloteau I, Sherif B, Williams N, Guana A, Lebwohl MG (2018) Effect of Secukinumab on quality of life and Psoriasis-related symptoms: a comparative analysis versus Ustekinumab from the CLEAR 52-week study. J Am Acad Dermatol 78(4):741\u2013748. https:\/\/doi.org\/10.1016\/j.jaad.2017.10.025","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"1758_CR43","doi-asserted-by":"publisher","first-page":"971","DOI":"10.2340\/00015555-3245","volume":"99","author":"L Puig","year":"2019","unstructured":"Puig L, Dossenbach M, Berggren L, Ljungberg A, Zachariae C (2019) Absolute and relative Psoriasis area and severity indices (PASI) for comparison of the efficacy of Ixekizumab to Etanercept and placebo in patients with moderate-to-severe plaque Psoriasis: An integrated analysis of UNCOVER-2 and UNCOVER-3 outcomes. Acta Dermato-Venereol 99(11):971\u2013977. https:\/\/doi.org\/10.2340\/00015555-3245","journal-title":"Acta Dermato-Venereol"},{"key":"1758_CR44","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1038\/jid.2015.394","volume":"135","author":"K Reich","year":"2015","unstructured":"Reich K, Toth D, Nikai E, Zhu B, Carlier H, Feldman S, Reich K, Toth D, Nikai E, Zhu B, Carlier H, Feldman S (2015) Ixekizumab impact on health-related quality of life compared to Etanercept and placebo: Results from UNCOVER-2, a phase 3 trial in patients with moderate-to-severe plaque Psoriasis. J Investig Dermatol 135:S35\u2013S35","journal-title":"J Investig Dermatol"},{"issue":"3","key":"1758_CR45","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"K Reich","year":"2017","unstructured":"Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, Li S, Shen YK, Gordon KB (2017a) Efficacy and safety of Guselkumab, an anti-interleukin-23 monoclonal antibody, compared with Adalimumab for the treatment of patients with moderate to severe Psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol 76(3):418\u2013431. https:\/\/doi.org\/10.1016\/j.jaad.2016.11.042","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1758_CR46","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/jdv.14015","volume":"31","author":"K Reich","year":"2017","unstructured":"Reich K, Gooderham M, Green L, Bewley A, Zhang Z, Khanskaya I, Day R, Goncalves J, Shah K, Piguet V, Soung J, Reich K, Gooderham M, Green L, Bewley A, Zhang Z, Khanskaya I, Day RM, Goncalves J et al (2017b) The efficacy and safety of Apremilast, Etanercept and placebo in patients with moderate-to-severe plaque Psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE). J Eur Acad Dermatol Venereol 31(3):507\u2013517. https:\/\/doi.org\/10.1111\/jdv.14015","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10091","key":"1758_CR47","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/s0140-6736(17)31279-5","volume":"390","author":"K Reich","year":"2017","unstructured":"Reich K, Papp KA, Blauvelt A, Tyring SK, Sinclair R, Tha\u00e7i D, Nograles K, Mehta A, Cichanowitz N, Li Q, Liu K, La Rosa C, Green S, Kimball AB (2017c) Tildrakizumab versus placebo or Etanercept for chronic plaque Psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet 390(10091):276\u2013288. https:\/\/doi.org\/10.1016\/s0140-6736(17)31279-5","journal-title":"Lancet"},{"issue":"4","key":"1758_CR48","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1111\/bjd.15666","volume":"177","author":"K Reich","year":"2017","unstructured":"Reich K, Pinter A, Lacour JP, Ferrandiz C, Micali G, French LE, Lomaga M, Dutronc Y, Henneges C, Wilhelm S, Hartz S, Paul C (2017d) Comparison of Ixekizumab with Ustekinumab in moderate-to-severe Psoriasis: 24-week results from IXORA-S, a phase III study. Br J Dermatol 177(4):1014\u20131023. https:\/\/doi.org\/10.1111\/bjd.15666","journal-title":"Br J Dermatol"},{"issue":"10201","key":"1758_CR49","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/s0140-6736(19)31773-8","volume":"394","author":"K Reich","year":"2019","unstructured":"Reich K, Armstrong AW, Langley RG, Flavin S, Randazzo B, Li S, Hsu MC, Branigan P, Blauvelt A (2019a) Guselkumab versus Secukinumab for the treatment of moderate-to-severe Psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet 394(10201):831\u2013839. https:\/\/doi.org\/10.1016\/s0140-6736(19)31773-8","journal-title":"Lancet"},{"issue":"10198","key":"1758_CR50","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/s0140-6736(19)30952-3","volume":"394","author":"K Reich","year":"2019","unstructured":"Reich K, Gooderham M, Tha\u00e7i D, Crowley JJ, Ryan C, Krueger JG, Tsai TF, Flack M, Gu Y, Williams DA, Thompson EHZ, Paul C (2019b) Risankizumab compared with Adalimumab in patients with moderate-to-severe plaque Psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet 394(10198):576\u2013586. https:\/\/doi.org\/10.1016\/s0140-6736(19)30952-3","journal-title":"Lancet"},{"issue":"10273","key":"1758_CR51","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/s0140-6736(21)00125-2","volume":"397","author":"K Reich","year":"2021","unstructured":"Reich K, Papp KA, Blauvelt A, Langley RG, Armstrong A, Warren RB, Gordon KB, Merola JF, Okubo Y, Madden C, Wang M, Cioffi C, Vanvoorden V, Lebwohl M (2021) Bimekizumab versus Ustekinumab for the treatment of moderate to severe plaque Psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet 397(10273):487\u2013498. https:\/\/doi.org\/10.1016\/s0140-6736(21)00125-2","journal-title":"Lancet"},{"issue":"2","key":"1758_CR52","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1202a104","volume":"12","author":"K Reich","year":"2022","unstructured":"Reich K, Kristensen LE, Smith SD, Rich P, Sapin C, Leage SL, McKenzie R, Schuster C, Riedl E, Gooderham M (2022) Efficacy and safety of ixekizumab versus adalimumab in biologic-na\u00efve patients with active psoriatic arthritis and moderate-to-severe psoriasis: 52-week results from the randomized SPIRIT-H2H trial. Dermatol Pract Concept 12(2):e2022104. https:\/\/doi.org\/10.5826\/dpc.1202a104","journal-title":"Dermatol Pract Concept"},{"issue":"2","key":"1758_CR53","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s13555-023-01092-x","volume":"14","author":"K Reich","year":"2024","unstructured":"Reich K, Bianchi L, Khemis A, Maul JT, Tsianakas A, Schempp CM, Petersen K, Noergaard MM, Puig L (2024) Brodalumab versus guselkumab in patients with moderate-to-severe psoriasis with an inadequate response to ustekinumab: a randomized, multicenter, double-blind phase 4 trial (COBRA). Dermatol Ther (Heidelb) 14(2):453\u2013468. https:\/\/doi.org\/10.1007\/s13555-023-01092-x","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"1758_CR54","doi-asserted-by":"publisher","first-page":"CD011535","DOI":"10.1002\/14651858.CD011535.pub5","volume":"5","author":"E Sbidian","year":"2022","unstructured":"Sbidian E, Chaimani A, Garcia-Doval I, Doney L, Dressler C, Hua C, Hughes C, Naldi L, Afach S, Le Cleach L (2022) Systemic pharmacological treatments for chronic plaque Psoriasis: a network meta-analysis. Cochrane Database Syst Rev 5(5):CD011535. https:\/\/doi.org\/10.1002\/14651858.CD011535.pub5","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"1758_CR55","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1093\/bjd\/ljad252","volume":"189","author":"LF Stein Gold","year":"2023","unstructured":"Stein Gold LF, Bagel J, Tyring SK, Hong HC, Pavlovsky L, Vender R, Pinter A, Reich A, Drogaris L, Wu T, Patel M, Soliman AM, Photowala H, Stakias V, Richter S, Papp KA (2023) Comparison of Risankizumab and Apremilast for the treatment of adults with moderate plaque Psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse). Br J Dermatol 189(5):540\u2013552. https:\/\/doi.org\/10.1093\/bjd\/ljad252","journal-title":"Br J Dermatol"},{"issue":"1","key":"1758_CR56","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","volume":"88","author":"B Strober","year":"2023","unstructured":"Strober B, Tha\u00e7i D, Sofen H, Kircik L, Gordon KB, Foley P, Rich P, Paul C, Bagel J, Colston E, Throup J, Kundu S, Sekaran C, Linaberry M, Banerjee S, Papp KA (2023) Deucravacitinib versus placebo and Apremilast in moderate to severe plaque Psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor Psoriasis second trial. J Am Acad Dermatol 88(1):40\u201351. https:\/\/doi.org\/10.1016\/j.jaad.2022.08.061","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1758_CR57","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1111\/bjd.16366","volume":"178","author":"DE Stull","year":"2018","unstructured":"Stull DE, Griffiths CEM, Gilloteau I, Zhao Y, Guana A, Finlay AY, Sherif B, Houghton K, Puig L (2018) Differential effects of Secukinumab vs. Ustekinumab for treatment of Psoriasis on quality of life, work productivity and activity impairment: a structural equation modelling analysis. Br J Dermatol 178(6):1297\u20131307. https:\/\/doi.org\/10.1111\/bjd.16366","journal-title":"Br J Dermatol"},{"issue":"3","key":"1758_CR58","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.jaad.2015.05.013","volume":"73","author":"D Tha\u00e7i","year":"2015","unstructured":"Tha\u00e7i D, Blauvelt A, Reich K, Tsai TF, Vanaclocha F, Kingo K, Ziv M, Pinter A, Hugot S, You R, Milutinovic M (2015) Secukinumab is superior to Ustekinumab in clearing skin of subjects with moderate to severe plaque Psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol 73(3):400\u2013409. https:\/\/doi.org\/10.1016\/j.jaad.2015.05.013","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"1758_CR59","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1111\/jdv.13702","volume":"30","author":"F Valenzuela","year":"2016","unstructured":"Valenzuela F, Paul C, Mallbris L, Tan H, Papacharalambous J, Valdez H, Mamolo C (2016) Tofacitinib versus Etanercept or placebo in patients with moderate to severe chronic plaque Psoriasis: patient-reported outcomes from a Phase 3 study. J Eur Acad Dermatol Venereol 30(10):1753\u20131759. https:\/\/doi.org\/10.1111\/jdv.13702","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1758_CR60","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.ad.2017.02.005","volume":"108","author":"F Valenzuela","year":"2017","unstructured":"Valenzuela F, de la Cruz Fernandez C, Galimberti RL, G\u00fcrb\u00fcz S, McKean-Matthews M, Goncalves L, Romiti R (2017) Comparison of Ixekizumab with Etanercept or placebo in moderate-to-severe Psoriasis: subgroup analysis of Latin American patients in the phase 3 randomized UNCOVER-3 study. Actas Dermosifiliogr 108(6):550\u2013563. https:\/\/doi.org\/10.1016\/j.ad.2017.02.005","journal-title":"Actas Dermosifiliogr"},{"issue":"1","key":"1758_CR61","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/bjd.19341","volume":"184","author":"RB Warren","year":"2021","unstructured":"Warren RB, Blauvelt A, Poulin Y, Beeck S, Kelly M, Wu T, Geng Z, Paul C (2021a) Efficacy and safety of Risankizumab vs. Secukinumab in patients with moderate-to-severe plaque Psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial. Br J Dermatol 184(1):50\u201359. https:\/\/doi.org\/10.1111\/bjd.19341","journal-title":"Br J Dermatol"},{"issue":"2","key":"1758_CR62","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/jdv.16816","volume":"35","author":"RB Warren","year":"2021","unstructured":"Warren RB, Hansen JB, Reich K, Paul C, Puig L (2021b) Complete clearance and Psoriasis area and severity index response for Brodalumab and Ustekinumab in AMAGINE-2 and -3. J Eur Acad Dermatol Venereol 35(2):450\u2013457. https:\/\/doi.org\/10.1111\/jdv.16816","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1758_CR63","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1080\/09546634.2020.1770174","volume":"33","author":"SW Youn","year":"2022","unstructured":"Youn SW, Yu DY, Kim TY, Kim BS, Lee SC, Lee JH, Choe YB, Lee JH, Choi JH, Roh JY, Jo SJ, Lee ES, Shin MK, Lee MG, Jiang J, Lee Y (2022) Efficacy and safety of Guselkumab compared with placebo and Adalimumab in Korean patients with moderate-to-severe Psoriasis: post-hoc analysis from the phase III, double-blind, placebo- and active-comparator-controlled VOYAGE 1\/2 trials. J Dermatol Treat 33(1):535\u2013541. https:\/\/doi.org\/10.1080\/09546634.2020.1770174","journal-title":"J Dermatol Treat"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-01758-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-025-01758-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-01758-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T06:07:12Z","timestamp":1750226832000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-025-01758-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":63,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1758"],"URL":"https:\/\/doi.org\/10.1007\/s10787-025-01758-2","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"24 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors declare that there is no conflict of interest for this project.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All collected data were kept confidential and analysed without specific names attached. The study adhered to Helsinki ethical principles. The project was registered at Iran University of Medical Sciences with registration No. IR.IUMS.ZS5453632655231Z1, bearing the scientific title \"Systematic Review of Comparative Studies on Emerging Psoriasis Treatments: Comparing Biologics with Biologics, Small Molecule Inhibitors with Small Molecule Inhibitors, and Biologics with Small Molecule Inhibitors\" It was approved by the Research Council under the ethics code number IR.IUMS.FMD.REC.1403.645.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical principles and consent to participate"}},{"value":"The authors obtained consent to publish. The current manuscript contains no individual person\u2019s data. Therefore, consent to publish is not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}